Combined cord blood and bone marrow transplantation from the same human leucocyte antigen‐identical sibling donor for children with malignant and non‐malignant diseases

Umbilical cord blood (UCB) from an human leucocyte antigen (HLA)‐identical sibling can be used for transplantation of patients with malignant and non‐malignant diseases. However, the low cellular content of most UCB units represents a limitation to this approach. An option to increase cell dose is to harvest bone marrow (BM) cells from the same donor and infuse them along with the UCB. We studied 156 children who received such a combined graft between 1992 and 2011. Median age was 7 years and 78% of patients (n = 122) were transplanted for non‐malignant diseases, mainly haemoglobinopathies. Acute leukaemia (n = 26) was the most frequent malignant diagnosis. Most patients (91%) received myeloablative conditioning. Median donor age was 1·7 years, median infused nucleated cell dose was 24·4 × 107/kg and median follow‐up was 41 months. Sixty‐days neutrophil recovery occurred in 96% of patients at a median of 17 d. The probabilities of grade‐II‐IV acute and chronic graft‐versus‐host disease (GVHD) were 19% and 10%, respectively. Four‐year overall survival was 90% (68% malignant; 97% non‐malignant diseases) with 3% probability of death. In conclusion, combined UCB and BM transplantation from an HLA‐identical sibling donor is an effective treatment for children with malignant and non‐malignant disorders with high overall survival and low incidence of GVHD.

[1]  A. Scaradavou,et al.  Combined umbilical cord blood and bone marrow from HLA‐identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies , 2014, Pediatric blood & cancer.

[2]  L. Pierelli,et al.  Total nucleated cells as a sole predictor of distinct targets of hematopoietic potential (CD34+ cells) in cord blood units: the results of a large series analysis in autologous cord blood units , 2014, Transfusion.

[3]  M. Yoder.  Cord blood banking and transplantation: advances and controversies , 2014, Current opinion in pediatrics.

[4]  K. Ballen,et al.  Umbilical cord blood transplantation: the first 25 years and beyond. , 2013, Blood.

[5]  J. Wagner,et al.  Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. , 2013, Blood.

[6]  J. Kurtzberg,et al.  Impact of Selection of Cord Blood Units from the United States and Swiss Registries on the Cost of Banking Operations , 2013, Transfusion Medicine and Hemotherapy.

[7]  G. Dini,et al.  Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. , 2012, Blood.

[8]  J. Kurtzberg,et al.  Family-directed umbilical cord blood banking , 2011, Haematologica.

[9]  E. Gluckman.  Milestones in umbilical cord blood transplantation. , 2011, Blood reviews.

[10]  M. Chandy,et al.  HLA-matched sibling bone marrow transplantation for β-thalassemia major. , 2011, Blood.

[11]  F. Locatelli,et al.  Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. , 2010, Blood.

[12]  A. Scaradavou,et al.  Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. , 2010, Blood.

[13]  I. Millán,et al.  Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor , 2009, Bone Marrow Transplantation.

[14]  J. Klein,et al.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study , 2007, The Lancet.

[15]  Todd E DeFor,et al.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.

[16]  M. Labopin,et al.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. , 2004, The New England journal of medicine.

[17]  J. Wagner,et al.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. , 2004, The New England journal of medicine.

[18]  S. Chevret,et al.  Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. , 2004, Experimental hematology.

[19]  J Wagner,et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. , 2002, Blood.

[20]  A. Zander,et al.  Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. , 2001, Blood.

[21]  J. Wagner,et al.  Graft versus Host Disease in Children Who Have Received a Cord Blood or Bone Marrow Transplant from HLA‐Identical Siblings , 2000 .

[22]  J. Klein,et al.  Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. , 2000, The New England journal of medicine.

[23]  I. Papassotiriou,et al.  COMBINED UMBILICAL CORD BLOOD AND BONE MARROW TRANSPLANT ATION IN THE TREATMENT OF BETA-THALASSEMIA MAJOR , 2000, Pediatric hematology and oncology.

[24]  F Locatelli,et al.  Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. , 1999, Blood.

[25]  Chi-kong Li,et al.  Neonatal blood: a source of haematopoietic stem cells for transplantation? , 1998, The Lancet.

[26]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[27]  J. Kurtzberg,et al.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.

[28]  G. Sirchia,et al.  Combined transplantation with related HLA‐identical cord blood and bone marrow in a child with severe acquired aplastic anaemia , 1996, European journal of haematology.

[29]  J. Wagner,et al.  Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease , 1995, The Lancet.

[30]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[31]  J. Kurtzberg,et al.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  C. Grady,et al.  Children as hematopoietic cell donors in research: when is it approvable? , 2015, Bone Marrow Transplantation.

[34]  F. Locatelli,et al.  Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. , 2013, Blood.

[35]  M. Gordon.  Transplants of Umbilical-Cord Blood or Bone Marrow From Unrelated Donors in Adults With Acute Leukemia , 2006 .

[36]  P. Warkentin.  Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT). , 2003, Cytotherapy.

[37]  ohn,et al.  The GRAFT-VERSUS-HOST DISEASE IN CHILDREN WHO HAVE RECEIVED A CORD-BLOOD OR BONE MARROW TRANSPLANT FROM AN HLA-IDENTICAL SIBLING , 2000 .

[38]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. , 1997, The New England journal of medicine.

[39]  D.,et al.  Regression Models and Life-Tables , 2022 .